Antonio Freire

Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial

Ernst-Rüdiger Kuse, Ploenchan Chetchotisakd, Clóvis Arns da Cunha et al. · The Lancet · 2007 · 689 citations

Invasive Candidosis, Antifungal Agent, Antifungal Agents +8

Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia

Antonio Freire, Vasyl Melnyk, Min Ja Kim et al. · Diagnostic Microbiology and Infectious Disease · 2010 · 283 citations

Health Sciences, Antibiotics, Healthcare-associated Infection +8

Micafungin Versus Liposomal Amphotericin B for Pediatric Patients With Invasive Candidiasis

Flávio Queiroz‐Telles, Eitan Naaman Berezin, Guy Leverger et al. · The Pediatric Infectious Disease Journal · 2008 · 214 citations

Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Alexander P. J. Vlaar, Martin Witzenrath, Pieter van Paassen et al. · The Lancet Respiratory Medicine · 2022 · 131 citations · Full text

Critical Care Medicine, Clinical Infectious Disease, Anti-c5a Antibody +6

Pharmacokinetics of Micafungin in Pediatric Patients With Invasive Candidiasis and Candidemia

Nasrullah Undre, Paul Stevenson, Antonio Freire et al. · The Pediatric Infectious Disease Journal · 2012 · 37 citations

Antifungal Agent, Antibiotics, Antifungal Agents +15